On the afternoon of August 18, Sino Biopharm (1177.HK) held its interim results conference in Hong Kong, continuing its outstanding performance of high growth in revenue and net profit: In the first half of 2025, the company's revenue reached RMB 17.57 billion, with a year-on-year increase of 10.7%; the net profit attributable to owners of the parent from continuing operations was RMB 3.39 billion, with a substantial increase of 140.2%; and the adjusted net profit attributable to owners of the parent was RMB 3.09 billion, with a year-on-year increase of 101.1%.

On July 15, Sino Biopharm (1177.HK) made a major announcement that it will acquire 100% of LaNova Medicines Ltd. for a net consideration of approximately US$500 million.

On the afternoon of July 6, at the 42nd China Pharmaceutical Industry Information Annual Conference, the "2024 Top 100 Pharmaceutical Companies in China" list was officially released.

Recently, the 2025 "Forbes China's Top 100 Outstanding Businesswomen" list was officially released. Miss Theresa Tse, Chairwoman of the Board of Sino Biopharm (1177.HK), was named to the list, marking the seventh time she has been honored with this award.